 "Chhattisgarh may sue Cipla for not meeting remdesivir supply requirements")
The Chhattisgarh government is considering legal action against pharma major Cipla for not meeting the supply requirements for Covid-19 antiviral drug Remdesivir.
Calling it a breach of contract by Cipla, Chhattisgarh Health Minister T S Singh Deo said the state was forced to buy the antiviral from another pharma company at twice the price. According to Singh Deo, the Indian pharma major had reneged on the contract signed on April 3 to supply Remdesivir injections to the state at the rate of Rs 594 plus 12 per cent goods and services tax (GST) per dose.
With Cipla not
Calling it a breach of contract by Cipla, Chhattisgarh Health Minister T S Singh Deo said the state was forced to buy the antiviral from another pharma company at twice the price. According to Singh Deo, the Indian pharma major had reneged on the contract signed on April 3 to supply Remdesivir injections to the state at the rate of Rs 594 plus 12 per cent goods and services tax (GST) per dose.
With Cipla not
